Balyasny Asset Management LLC Viking Therapeutics, Inc. Call Options Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$49.84 - $70.47 $1.49 Million - $2.1 Million
-29,800 Reduced 51.92%
27,600 $1.75 Million
Q2 2024

Aug 14, 2024
BUY
$47.39 - $80.2 $2.72 Million - $4.6 Million
57,400 New
57,400 $3.04 Million
Q4 2023

Feb 14, 2024
SELL
$9.24 - $19.64 $8.45 Million - $18 Million
-915,000 Reduced 87.98%
125,000 $2.33 Million
Q3 2023

Nov 14, 2023
BUY
$10.92 - $16.0 $11.4 Million - $16.6 Million
1,040,000 New
1,040,000 $11.5 Million

Others Institutions Holding VKTX

# of Institutions
473
Shares Held
65.6M
Call Options Held
5.72M
Put Options Held
3.39M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email